An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid Tumors
Condition(s):Malignant Solid Tumour; Ovarian Cancer; Triple Negative Breast Cancer; Advanced Melanoma; B-cell Malignancy, Low-gradeLast Updated:June 18, 2023Completed